GeneSort
A molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | €20.9m | Acquisition | |
| Total Funding | 000k | ||
Related Content
GeneSort, founded in September 2013, operates in the molecular diagnostics sector with a specific focus on integrating genomics with personalized therapeutic strategies. Based in Herzliya, Israel, the company directs its diagnostic services towards oncology and the identification of hereditary diseases. The core of GeneSort's business is to analyze the unique genetic profile of a patient's DNA to help physicians determine safer and more effective treatment plans.
The company's business model revolves around providing specialized diagnostic services to healthcare providers. By analyzing a patient's genetic makeup, GeneSort offers critical information for diagnosing, treating, and preventing illnesses. In the realm of oncology, this involves profiling tumors to guide targeted drug selection, monitor for drug resistance, and assess the efficacy of immunotherapy. For hereditary diseases, the service aids in confirming diagnoses where clinical symptoms may be ambiguous and helps in assessing risk for family members, which can inform preconception or prenatal testing decisions. Revenue is generated through the provision of these advanced genetic testing services.
A significant milestone in the company's history was its acquisition by the Hong Kong-based investment fund, AID Partners, on May 9, 2017, for $23 million. Prior to this, in 2015, GeneSort had secured an undisclosed amount in an Angel funding round from the investor Singulariteam. The company was noted as being under the leadership of Dr. Ayala Lagziel at the time of its partnership with AID Partners. Following the acquisition, GeneSort was presumed to be inactive as of August 2018, having been integrated into its parent organization.
Keywords: molecular diagnostics, personalized medicine, cancer diagnostics, hereditary disease testing, genetic profiling, genomics, DNA analysis, oncology testing, pharmacogenetics, tumor profiling, genetic screening, liquid biopsy, next-generation sequencing, precision medicine, treatment selection, Israeli startup, Health Tech, Life Sciences, AID Partners, Singulariteam